News
- Abbott to Acquire Solvay Pharmaceuticals Business
- Health Canada Approves Abbott’s XIENCE V® Drug Eluting Stent
- Interim Results of Abbott’s PROGRESS Study Show Rapid Viral Decline in Dual-Therapy Regimen of Kaletra (lopinavir/ritonavir) and Raltegravir
- Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
- Abbott Announces 11 Percent Increase in Quarterly Dividend
- Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
View more news from Abbott Canada | Abbott Global
